What is Perandren?
Perandren is a naturally occurring sex hormone produced in a man's testicles. Small amounts of Perandren are also produced in a woman's ovaries and adrenal system.
Perandren is used in men and boys to treat conditions caused by a lack of this hormone, such as delayed puberty, impotence, or other hormonal imbalances. This medicine is not for use in treating low Perandren without certain medical conditions or due to getting older.
Perandren enanthate is used in women to treat breast cancer that has spread to other parts of the body (metastatic) and cannot be treated with surgery.
Perandren will not enhance athletic performance and should not be used for that purpose.
Perandren may also be used for purposes not listed in this medication guide.
Perandren indications
Perandren Gel 1% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous Perandren:
- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum Perandren concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low Perandren serum concentrations, but have gonadotropins in the normal or low range.
Limitations of use:
- Safety and efficacy of Perandren Gel 1% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
- Safety and efficacy of Perandren Gel 1% in males less than 18 years old have not been established.
Topical Perandren products may have different doses, strengths or application instructions that may result in different systemic exposure (1, 12.3).
How should I use Perandren?
Use Perandren solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Perandren solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Perandren solution refilled.
- Prime this product before the first use. To prime it, depress the pump 3 times and wash any product that is dispensed down the sink.
- Depress the pump once to fill the applicator cup. Holding the applicator upright, wipe Perandren solution steadily up and down onto clean, dry skin in the armpit. If Perandren solution drips or runs, it can be wiped back up with the applicator cup. Do NOT apply Perandren solution to other parts of your body (eg, scrotum, penis, stomach, shoulders, upper arms). Do NOT apply it over open sores, wounds, or irritated skin.
- Do NOT use your fingers or hand to rub the medicine into the skin.
- You may need to alternate between armpits when applying Perandren solution. Be sure you understand how to apply Perandren solution. Contact your doctor or pharmacist if you have questions or concerns about how to apply Perandren solution.
- Wash your hands with soap and water immediately after using Perandren solution.
- Allow Perandren solution to dry completely before dressing.
- After Perandren solution has dried, cover the application site (eg, with a shirt) to prevent others from coming into contact with Perandren solution. If direct skin-to-skin contact with another person is expected, wash the application site well with soap and water to remove the medicine.
- After using Perandren solution, rinse the applicator with room temperature water and pat it dry with a tissue. Replace the applicator and cap on the bottle for storage.
- Do NOT get Perandren solution in your eyes. If you do, rinse thoroughly with water. If eye irritation persists, contact your doctor.
- Apply Perandren solution at the same time every morning after showering or bathing, unless your doctor tells you otherwise.
- If you are also using an antiperspirant or deodorant (stick or roll-on), apply it at least 2 minutes before you apply Perandren solution.
- For best results, wait 2 hours after applying Perandren solution before you wash the application site or swim.
- If you miss a dose of Perandren solution, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Perandren solution.
Uses of Perandren in details
Perandren is a male hormone primarily used to treat deficiency or absence of naturally produced hormone Perandren in men (hypogonadal disorders). The conditions include,
- Testicular diseases (primary hypogonadism) - diseases or conditions of testes, the organ that produces Perandren affecting secretion of Perandren.
- Pituitary diseases (secondary hypogonadism) - diseases or conditions of pituitary gland or hypothalamus that produce hormones (gonadotropins) which stimulate release of Perandren.
Perandren description
Perandren is a steroid sex hormone found in both men and women. In men, Perandren is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, Perandren is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Perandren exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Perandren may be further converted to dihydrotestosterone or estradiol depending on the tissue.
Perandren dosage
Perandren (Perandren (transdermal)) TTS
One system is applied at about the same time each day. The adhesive side of the Perandren (Perandren (transdermal)) TTS system should be placed on a clean, dry area of skin on the arm, back or upper buttocks immediately upon removal from the protective pouch. DO NOT APPLY TO THE SCROTUM. The area selected should not be oily, damaged, or irritated. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the system comes off after it has been worn for more than 12 hours and it cannot be reapplied, a new system may be applied at the next routine application time. In either case, the daily treatment schedule should be continued. The Perandren (Perandren (transdermal)) TTS system should be worn approximately 24 hours and then replaced. To ensure proper dosing, serum Perandren concentration may be measured 2-4 hours after an application of Perandren (Perandren (transdermal)) TTS. If the serum Perandren concentrations are low, the dosing regimen may be increased to 2 systems. Because of variability in analytical values among diagnostic laboratories, all Perandren measurements should be performed at the same laboratory.
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE
Patients should start therapy with a 6 mg/d system of either Perandren (Perandren (transdermal)) or Perandren (Perandren (transdermal)) WITH ADHESIVE applied daily; if the scrotal area cannot accommodate a 6 mg/d system, a 4 mg/d Perandren (Perandren (transdermal)) system should be used. One Perandren (Perandren (transdermal)) or Perandren (Perandren (transdermal)) WITH ADHESIVE system should be placed on clean, dry, scrotal skin. Scrotal hair should be dry-shaved for optimal skin contact. Chemical depilatories should not be used. Perandren (Perandren (transdermal)) or Perandren (Perandren (transdermal)) WITH ADHESIVE should be worn 22-24 hours.
After 3-4 weeks of daily system use, blood should be drawn 2-4 hours after system application for determination of serum total Perandren. Because of variability in analytical values among diagnostic laboratories, this laboratory work and later analyses for assessing the effect of the Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE therapy should be performed at the same laboratory.
If patients have not achieved desired results by the end of 6-8 weeks of treatment with any of the Perandren (Perandren (transdermal)) products, another form of Perandren replacement therapy should be considered.
How supplied
Perandren (Perandren (transdermal)) TTS, Perandren (Perandren (transdermal)), and Perandren (Perandren (transdermal)) WITH ADHESIVE Perandren transdermal systems contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Perandren (Perandren (transdermal)) TTS
Perandren (Perandren (transdermal)) TTS systems are supplied as individually pouched systems, 30 per carton. Perandren (Perandren (transdermal)) TTS 5 mg/d (Perandren Transdermal System) -- each 60 cm2 system contains 328 mg Perandren USP for nominal dose of 5 mg/day
Carton of 30 Perandren (Perandren (transdermal)) TTS 5 mg/d systemsNDC 17314-4717-3
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE systems are supplied as individually pouched systems, 30 per carton.
Perandren (Perandren (transdermal)) 4 mg/d (Perandren Transdermal System) -- each 40 cm2 system contains 10 mg Perandren USP for nominal delivery of 4 mg for one day.
Carton of 30 Perandren (Perandren (transdermal)) 4 mg/d systems. NDC 17314-4608-3
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE
6 mg/d (Perandren Transdermal System) -- each 60 cm2 system contains 15 mg Perandren USP for nominal delivery of 6 mg for one day.
Carton of 30 Perandren (Perandren (transdermal)) 6 mg/d systems. NDC 17314-4609-3
Carton of 30 Perandren (Perandren (transdermal)) WITH ADHESIVE 6 mg/d systemsNDC 17314-2836-3
Storage
Perandren (Perandren (transdermal)) TTS
Store at controlled room temperature below 25oC (77oF).
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE
Store at room temperature 15-30oC (59-86oF).
Disposal
Perandren (Perandren (transdermal)) products should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.
Caution: Federal law prohibits dispensing without prescription.
REFERENCE
1. Matsumoto AM, Sandblom RE, Schoene RB et al. Perandren replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (1985) 22: 713-721.
2. Schneider BK, Pickett CK, Zwillich CW et al. Influence of Perandren on breathing during sleep. J Appl Physiol (1986) 61: 618-623.
3. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. (1994) 23: 857-875.
4. Bardin CW, Swerdloff RS, Santen RJ. Androgens: Risks and benefits. J Clin Endocinol Metab (1991) 73: 4-7.
5. Nieschlag E, Wang CCL. Guidelines for the use of androgens in men. Geneva: World Health Organization (1992); 1-16.
6. Walle T, Walle UK, Mathur RS et al. Propranolol metabolism in normal subjects: Association with sex steroid hormones. Curr Pharmacol Ther (1994) 56:127-132.
7. Physicians Generic Rx: The Complete Drug Reference. (1996); II-1972
Perandren interactions
See also:
What other drugs will affect Perandren?
Drug Interactions
Anticoagulants: C-17 substituted derivatives of Perandren, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped.
Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
Propranolol: In a published pharmacokinetic study of an injectable Perandren product, administration of Perandren cypionate led to an increased clearance of propranolol in the majority of men tested.6
Corticosteroids: The concurrent administration of Perandren with ACTH or corticosteroids may enhance edema formation; thus these drugs should be administered cautiously, particularly in patients with cardiac or hepatic disease.7
Drug/Laboratory Test Interactions
Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
The Perandren (Perandren (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Perandren (Perandren (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Perandren than other skin sites, Perandren (Perandren (transdermal)) or Perandren (Perandren (transdermal)) WITH ADHESIVE will not produce adequate serum Perandren concentrations if applied to non-scrotal skin.
Ingestion of Perandren, or the contents of any of the Perandren (Perandren (transdermal)) products will not result in clinically significant serum Perandren concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Perandren from any of the Perandren (Perandren (transdermal)) products will not produce adequate serum Perandren levels due to its short half-life (about 10 minutes).
Perandren side effects
See also:
What are the possible side effects of Perandren?
Adverse events are reported in this section by product. Adverse events reported during use of a given product may occur in patients who are treated with any Perandren (Perandren (transdermal)) product.
Adverse Events with Perandren (Perandren (transdermal)) TTS
In clinical studies of 457 participants (116 hypogonadal males and 341 healthy adult males) treated for up to 6 weeks with Perandren (Perandren (transdermal)) TTS, the most commonly reported adverse events were application site reactions of transient itching (12%) and moderate or severe erythema (3%).
Adverse events reported by less than 1% of Perandren (Perandren (transdermal)) TTS users in clinical trials that were of probable or unknown relationship to drug were:
Topical Reactions
Of 457 study participants, 3 men (1%) discontinued prematurely because of application site reactions.
There were no clinically significant differences in skin tolerability in younger (<65 years old) and older (³ 65 years old) subjects.
A contact sensitization rate of 0.5% for Perandren (Perandren (transdermal)) TTS was observed in a 6-week study of 233 normal male volunteers.
In one study with 14 days of daily use, 42% of patients reported 3 or more detachments of their Perandren (Perandren (transdermal)) TTS; of these detachments, 33% occurred during exercise.
Adverse Events with Perandren (Perandren (transdermal))
In clinical studies of 104 patients treated with Perandren (Perandren (transdermal)), the most common adverse effects reported were local effects. In US clinical trials, most of the 72 patients filling out a daily questionnaire reported scrotal itching, discomfort, or irritation at some time during therapy. Of all the daily questionnaire responses, 7% reported itching, 4% discomfort, and 2% irritation. All topical reactions decreased with duration of use.
The following adverse effects (greater than 1%) were reported in association with Perandren (Perandren (transdermal)) therapy in 104 patients using the product for up to three years. These effects are listed in decreasing frequency of occurrence with the percentages of patients reporting the effect in parentheses: Gynecomastia (5%), acne (4%), prostatitis/urinary tract infection (4%), breast tenderness (3%), stroke (2%). For this same patient population, the following adverse effects were reported by 1% of users: memory loss, pupillary dilation, abnormal liver enzymes, scrotal cellulitis, deep vein phlebitis, benign prostatic hyperplasia, rectal mucosal lesion over prostate, hematuria/bladder cancer, papilloma on scrotum, and congestive heart failure.
Adverse Events with Perandren (Perandren (transdermal)) WITH ADHESIVE
In a pharmacokinetic study in 50 normal men, skin assessment scores following a single 24-hour application of Perandren (Perandren (transdermal)) WITH ADHESIVE to scrotal skin were similar to those for Perandren (Perandren (transdermal)). Other adverse events reported during the study were headache (6%), dizziness (6%), back pain, pain, nausea, and pustular rash (1% each).
General Adverse Events with Androgen Replacement Therapy
Skin and Appendages: Hirsutism, male pattern baldness, seborrhea, and acne.
Endocrine and Urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high doses.
Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests. Rare instances of hepatocellular neoplasms and peliosis hepatis have occurred.
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Metabolic: Increased serum cholesterol.
Miscellaneous: Rarely, anaphylactoid reactions.
DRUG ABUSE AND DEPENDENCE
The Perandren (Perandren (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Perandren (Perandren (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.
Perandren (Perandren (transdermal)) and Perandren (Perandren (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Perandren than other skin sites, Perandren (Perandren (transdermal)) or Perandren (Perandren (transdermal)) WITH ADHESIVE will not produce adequate serum Perandren concentrations if applied to non-scrotal skin.
Ingestion of Perandren, or the contents of any of the Perandren (Perandren (transdermal)) products will not result in clinically significant serum Perandren concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Perandren from any of the Perandren (Perandren (transdermal)) products will not produce adequate serum Perandren levels due to its short half-life (about 10 minutes).
Perandren contraindications
See also:
What is the most important information I should know about Perandren?
-
Perandren Gel 1% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate.
-
Perandren Gel 1% is contraindicated in women who are or may become pregnant, or who are breastfeeding. Perandren Gel 1% may cause fetal harm when administered to a pregnant woman. Perandren Gel 1% may cause serious adverse reactions in nursing infants. Exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization. Pregnant women or those who may become pregnant need to be aware of the potential for transfer of Perandren from men treated with Perandren Gel 1%. If a pregnant woman is exposed to Perandren Gel 1%, she should be apprised of the potential hazard to the fetus.
Active ingredient matches for Perandren:
List of Perandren substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Pasoma (Ethiopia) | |
Percutacrine Androgenique | |
PMS-Testosterone (Canada) | |
PMS-testosterone capsule 40 mg (Pharmascience Inc (Canada)) | |
PMS-Testosterone Enanthate | |
Injectable; Injection; Testosterone Enanthate 200 mg / ml | |
PMS-Testosterone Undecanoate | |
Capsule; Oral; Testosterone Undecanoate 40 mg | |
Polysteron 250 (Venezuela) | |
Primoniat Depot (Chile) | |
Injectable; Injection; Testosterone Enanthate 250 mg / ml | |
Primotest | |
Primoteston | |
Primoteston Depot (Australia, Ecuador) | |
Injectable; Injection; Testosterone Enanthate | |
Primotestone | |
Propiokan | |
Reandron (Australia, New Zealand, Spain) | |
Injectable; Injection; Testosterone Undecanoate 250 mg / ml | |
Reandron 1000 (Australia, New Zealand) | |
Recthormone | |
Relibra | |
Restandol (Greece, Ireland, Malta, United Kingdom) | |
Capsule; Oral; Testosterone Undecanoate 40 mg | |
Restandol Orifarm (Denmark) | |
Ropel Liquid Testosterone (Australia) | |
Ropel Liquid Testosterone for Wethers (Australia) | |
Scheinpharm Testone-Cyp | |
Injectable; Injection; Testosterone Cypionate 100 mg / ml | |
Si Te Long (China) | |
Solvotest | |
Sostenon (Mexico) | |
Injectable; Injection; Testosterone Decanoate 100 mg; Testosterone Isocaproate 60 mg; Testosterone Phenylpropionate 60 mg; Testosterone Propionate 30 mg / ml | |
Sostenon 250 | |
Injectable; Injection; Testosterone Decanoate 100 mg; Testosterone Isocaproate 60 mg; Testosterone Phenylpropionate 60 mg; Testosterone Propionate 30 mg / ml | |
Sterandryl | |
Striant SR | |
Tablet; Buccal, Oral; Testosterone 30 mg | |
Sustanon (Argentina, Australia, Bahrain, Bangladesh, Belgium, Cyprus, Czech Republic, Egypt, Estonia, Finland, Ghana, Hong Kong, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Netherlands, New Zealand, Oman, Qatar, Saudi Arabia, Singapore, Slovakia, Sudan, Syria, Tanzania, Turkey, United Arab Emirates, United Kingdom, Yemen, Zambia, Zimbabwe) | |
Injectable; Injection; Testosterone Decanoate 10%; Testosterone Isohexanoate 6%; Testosterone Phenylpropionate 6%; Testosterone Propionate 3% (Organon) | |
Sustanon Testosterone Propionate 20mg, Testosterone Phenylpropionate40mg, Testosterone Isocaproate40mg INJ / 1ml (Organon) | $ 0.55 |
Sustanon Testosterone Propionate 30mg, Testosterone Phenylpropionate60mg, Testosterone Isocaproate60mg, Testosterone Decanoate INJ / 1ml (Organon) | $ 1.84 |
1ml (Organon) | $ 1.84 |
Sustanon 1 mL x 1's (Organon) | |
SUSTANON inj 1ml (Organon) | $ 2.49 |
Sustanon inj 1 mL x 1's (Organon) | |
Sustanon 100mg Injection (Organon) | $ 1.58 |
Sustanon 250mg Injection (Organon) | $ 2.72 |
SUSTANON (ORGANON) | |
SUSTANON 100 MG INJECTION 1 vial / 1 ML injection each (Organon (India) Ltd) | $ 1.58 |
SUSTANON 250 MG INJECTION 1 vial / 1 ML injection each (Organon (India) Ltd) | $ 2.72 |
SUSTANON (SUN) | |
SUSTANON 100 MG INJECTION 1 vial / 1 ML injection each (Sun Pharma Laboratories Ltd) | $ 1.58 |
Sustanon 100 | |
Injectable; Injection; Testosterone Isohexanoate 6%; Testosterone Phenylpropionate 6%; Testosterone Propionate 3% (Organon (India) Ltd.) | |
Sustanon 100 1 ml Injection (Organon (India) Ltd.) | $ 1.28 |
Sustanon 250 (Argentina, Belgium, Kuwait, Luxembourg) | |
Injectable; Injection; Testosterone Decanoate 10%; Testosterone Isohexanoate 6%; Testosterone Phenylpropionate 6%; Testosterone Propionate 3% (Organon (India) Ltd.) | |
See 613 substitutes for Perandren |
References
- DailyMed. "TESTOSTERONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "testosterone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "testosterone". http://www.drugbank.ca/drugs/DB00624 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Perandren are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Perandren. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
2 consumers reported useful
Was the Perandren drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users | % | ||
---|---|---|---|
Not useful | 1 | 50.0% | |
Useful | 1 | 50.0% |
Consumer reported price estimates
No survey data has been collected yet3 consumers reported time for results
To what extent do I have to use Perandren before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 week and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Perandren. To get the time effectiveness of using Perandren drug by other patients, please click here.
Users | % | ||
---|---|---|---|
1 week | 2 | 66.7% | |
1 day | 1 | 33.3% |
8 consumers reported age
Users | % | ||
---|---|---|---|
46-60 | 4 | 50.0% | |
6-15 | 1 | 12.5% | |
16-29 | 1 | 12.5% | |
30-45 | 1 | 12.5% | |
< 1 | 1 | 12.5% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology